Sensitivity of murine B- and T-lymphocytes to oxazaphosphorine and non-oxazaphosphorine nitrogen mustardsSMITH, P. C; SLADEK, N. E.Biochemical pharmacology. 1985, Vol 34, Num 19, pp 3459-3463, issn 0006-2952Article

Ifosfamide metabolism and pharmacokinetics (review)KAIJSER, G. P; BEIJNEN, J. H; BULT, A et al.Anticancer research. 1994, Vol 14, Num 2A, pp 517-531, issn 0250-7005Article

Ifosfamide enantiomers : pharmacokinetics in childrenPRASAD, V. K; CORLETT, S. A; ABAASI, K et al.Cancer chemotherapy and pharmacology. 1994, Vol 34, Num 5, pp 447-449, issn 0344-5704Article

Bone marrow purging with mafosfamide: a critical surveySINDERMANN, H; PEUKERT, M; HILGARD, P et al.Blut. 1989, Vol 59, Num 5, pp 432-441, issn 0006-5242Article

The history of the oxazaphosphorine cytostaticsBROCK, N.Cancer. 1996, Vol 78, Num 3, pp 542-547, issn 0008-543XArticle

Degradation kinetics of ifosfamide in aqueous solutionMUNOZ, M; BONJOCH, J; PRAT, J et al.International journal of pharmaceutics. 1996, Vol 139, Num 1-2, pp 249-253, issn 0378-5173Article

Colorimetric determination of cyclophosphamide and ifosphamideMOHAMED, Z. H; AMER, S. M; EL-KOUSASY, A et al.Journal of pharmaceutical and biomedical analysis. 1994, Vol 12, Num 9, pp 1131-1136, issn 0731-7085Article

Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorinesKOHN, F. R; SLADEK, N. E.Biochemical pharmacology. 1985, Vol 34, Num 19, pp 3465-3471, issn 0006-2952Article

Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomasMICHELOTTI, A; ROMANINI, A; GIANNESSI, P et al.American journal of clinical oncology. 1996, Vol 19, Num 1, pp 78-81, issn 0277-3732Article

Intermediate doses of cyclophosphamide alone or following adriamycin in advanced breast cancer : a pilot studyZAMBETTI, M; TERENZIANI, M; BARTOLI, C et al.American journal of clinical oncology. 1996, Vol 19, Num 1, pp 82-86, issn 0277-3732Article

Phase II study of mitomycin, ifosfamide and cisplatin in adenocarcinoma of the oesophagusALLEN, S. M; DUFFY, J. P; DARNTON, S. J et al.Cancer chemotherapy and pharmacology. 1996, Vol 37, Num 5, pp 496-498, issn 0344-5704Article

Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patientsGRANVIL, C. P; DUCHARME, J; LEYLAND-JONES, B et al.Cancer chemotherapy and pharmacology. 1996, Vol 37, Num 5, pp 451-456, issn 0344-5704Article

Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancerKIRAZ, S; BALTALI, E; GÜLER, N et al.Journal of chemotherapy. 1996, Vol 8, Num 4, pp 310-314, issn 1120-009XArticle

The N-dechloroethylation of ifosfamide : using stereochemistry the obtain an accurate picture of a clinically relevant metabolic pathwayWAINER, I. W; DUCHARME, J; GRANVIL, C. P et al.Cancer chemotherapy and pharmacology. 1996, Vol 37, Num 4, pp 332-336, issn 0344-5704Article

Concentrating capacity in ifosfamide-induced severe renal dysfunctionROSSI, R; GÖDDE, A; KLEINEBRAND, A et al.Renal failure. 1995, Vol 17, Num 5, pp 551-557, issn 0886-022XArticle

Bone metabolism and mineralisation after cytotoxic chemotherapy including ifosfamideDE SCHEPPER, J; HACHIMI-IDRISSI, S; LOUIS, O et al.Archives of disease in childhood. 1994, Vol 71, Num 4, pp 346-348, issn 0003-9888Article

Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapyLAUTERBURG, B. H; NGUYEN, T; HARTMANN, B et al.Cancer chemotherapy and pharmacology. 1994, Vol 35, Num 2, pp 132-136, issn 0344-5704Article

High-dose ifosfamide by infusion with mesna in advanced refractory sarcomasGÜLLÜ, I; YALCIN, S; KANSU, E et al.Cancer investigation. 1996, Vol 14, Num 3, pp 239-242, issn 0735-7907Article

Separation of ifosfamide and its degradation products using micellar electrokinetic chromatographyHILL, S; AEXIOU, J; KAVANAGH, P. E et al.Analytical communications (Print). 1996, Vol 33, Num 7, pp 235-237, issn 1359-7337Article

MesnaLa Revue Prescrire. 1996, Vol 16, Num 158, issn 0247-7750, p. 31Article

Partitioning of ifosfamide and its metabolites between red blood cells and plasmaMOMERENCY, G; VAN CAUWENBERGHE, K; HIGHLEY, M. S et al.Journal of pharmaceutical sciences. 1996, Vol 85, Num 3, pp 262-265, issn 0022-3549Article

Risk factors for ifosfamide nephrotoxicity in childrenSKINNER, R; PEARSON, A. D. J; ENGLISH, M. W et al.Lancet (British edition). 1996, Vol 348, Num 9027, pp 578-580, issn 0140-6736Article

A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cyclesLEWIS, L. D.British journal of clinical pharmacology. 1996, Vol 42, Num 2, pp 179-186, issn 0306-5251Conference Paper

The determination of Ifosfamide in human blood serum using LC/MSSIETHOFF, C; NIGGE, W; LINSCHEID, M et al.Fresenius' journal of analytical chemistry. 1995, Vol 352, Num 7-8, pp 801-805, issn 0937-0633Article

Ifosfamide extravasationMATEU, J; ALZAMORA, M; FRANCO, M et al.The Annals of pharmacotherapy. 1994, Vol 28, Num 11, pp 1243-1244, issn 1060-0280Article